Regarding EGF, its administration attenuated lung inflammation and injury, probably through activating EGFR, leading to the suppression of NF-κB signaling, promotion of cell proliferation, and inhibition of apoptosis [39], as well as the prevention of systemic inflammatory response syndrome [40]. Here, NFKB1 is linked to systemic inflammatory response syndrome.